Seer’s Board rejected a $2.45 per share acquisition proposal, deeming it undervalued and not in stockholders' best interests.
Quiver AI Summary
Seer, Inc. announced that its Board of Directors' Special Committee has thoroughly reviewed and unanimously rejected a proposal from CEO Omid Farokhzad to acquire all outstanding shares of Seer’s Class A common stock for $2.45 per share, along with contingent value rights. The Committee, composed of independent directors, determined that the proposal undervalues Seer and does not adequately reflect the company's long-term growth prospects. They concluded that the included contingent value rights were insufficient to capture Seer's potential. Seer, a leader in proteomic insights, aims to enhance research through its innovative products, although they are not intended for diagnostic use.
Potential Positives
- The Special Committee's unanimous rejection of the acquisition proposal indicates confidence in Seer's long-term growth potential and valuation.
- The decision suggests that the company believes it is currently undervalued, which could reassure existing shareholders about the future value of their investment.
- The rejection of the proposal highlights Seer's commitment to maximizing shareholder value by seeking alternatives that fully reflect its growth prospects.
Potential Negatives
- The rejection of the acquisition proposal by their own CEO could indicate internal conflicts or a lack of alignment at the executive level, potentially unsettling investors.
- The Special Committee’s conclusion that the proposal undervalues Seer suggests that there may be skepticism regarding the company's current valuation or its future growth prospects, which may concern stakeholders.
- The proposal included contingent value rights that were deemed insufficient, indicating that the company may not have solid mechanisms in place to capitalize on future developments, potentially undermining investor confidence.
FAQ
What recent proposal did Seer, Inc. receive?
Seer received an unsolicited proposal from its CEO to acquire Class A common stock for $2.45 per share.
Why did the Special Committee reject the proposal?
The Special Committee determined the proposal undervalued Seer and didn’t reflect its long-term growth potential.
Who reviewed the acquisition proposal?
The proposal was reviewed by Seer’s Special Committee, composed of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D.
What are Seer's key products?
Seer specializes in deep proteomics with its Proteograph® Product Suite, which utilizes engineered nanoparticles and advanced analytical software.
Are Seer’s products intended for diagnostic use?
No, Seer’s products are for research use only and are not intended for diagnostic procedures.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SEER Insider Trading Activity
$SEER insiders have traded $SEER stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $SEER stock by insiders over the last 6 months:
- OMID FAROKHZAD (CEO AND CHAIR) sold 24,385 shares for an estimated $48,645
- DAVID R. HORN (PRESIDENT & CFO) has made 0 purchases and 2 sales selling 15,046 shares for an estimated $27,798.
- DIPCHAND NISHAR sold 10,660 shares for an estimated $23,265
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SEER Hedge Fund Activity
We have seen 16 institutional investors add shares of $SEER stock to their portfolio, and 31 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIREN, L.L.C. removed 1,541,327 shares (-38.5%) from their portfolio in Q1 2026, for an estimated $2,589,429
- FMR LLC removed 703,242 shares (-99.9%) from their portfolio in Q1 2026, for an estimated $1,181,446
- TWO SIGMA INVESTMENTS, LP added 258,951 shares (+102.5%) to their portfolio in Q1 2026, for an estimated $435,037
- RANGELEY CAPITAL, LLC added 164,302 shares (+821.5%) to their portfolio in Q1 2026, for an estimated $276,027
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 150,000 shares (-24.6%) from their portfolio in Q1 2026, for an estimated $252,000
- MILLENNIUM MANAGEMENT LLC removed 116,497 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $195,714
- JACOBS LEVY EQUITY MANAGEMENT, INC added 104,226 shares (+267.1%) to their portfolio in Q1 2026, for an estimated $175,099
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
REDWOOD CITY, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the Special Committee of Seer’s Board of Directors, consisting of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D., has thoroughly reviewed and unanimously rejected the unsolicited, non-binding proposal received on July 1, 2026, from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstanding shares of Seer’s Class A common stock for $2.45 per share in cash plus two separate contingent value rights (the “Proposal”).
Consistent with its fiduciary duties, the Special Committee carefully reviewed the Proposal in consultation with its independent advisors and unanimously determined that it is not in the best interests of Seer’s stockholders because it undervalues Seer and fails to reflect the value of Seer’s long-term growth prospects. In reaching this conclusion, the Special Committee noted that the contingent value rights included in the Proposal, which are intended to allow Seer’s stockholders to benefit from future developments related to Seer’s technology, were insufficient to fully value Seer and its growth potential.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph
®
Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit
www.seer.bio
.
For more information, please email us at [email protected] .
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s prospects, growth potential and technology. These and other risks are described more fully in Seer’s filings with the SEC and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:
Patrick Schmidt
[email protected]
Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Joseph Sala
(212) 355-4449
Investor Contact:
Marissa Bych
[email protected]
